Gastrointestinal Diseases Market, by Drug Category, and Geography – Global Opportunity Analysis and Industry Forecast, 2014 – 2022
October 2016
1
Table of Contents
1.1
Definitions ....................................................................................................................... 11
1.2
Research Methodology .................................................................................................... 11
1.3
Market Segmentation ...................................................................................................... 12
Executive Summary ................................................................................................................. 14 2.1
4
2.1.1 2022)
Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. ................................................................................................................................. 15
2.1.2 2021)
Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. ................................................................................................................................. 15
E
Market Dynamics ..................................................................................................................... 17 3.1
Drivers ............................................................................................................................. 17
3.2
Restraints ......................................................................................................................... 17
3.3
Opportunities ................................................................................................................... 17
3.4
Premium Industry Trends ................................................................................................. 18
PL
3
Market Summary: Global Gastrointestinal Diseases Market ............................................. 14
M
2
Market Overview ..................................................................................................................... 11
Industry Analysis...................................................................................................................... 19 4.1
Major Selling Drug Analysis .............................................................................................. 19
SA
1
4.1.1 (2015)
Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis ................................................................................................................................. 19
4.1.2
Nexium ..................................................................................................................... 19
4.1.3
Losec/Prilosec .......................................................................................................... 20
4.1.4
Dexilant .................................................................................................................... 20
4.1.5
Lialda........................................................................................................................ 20
4.1.6
Entyvio ..................................................................................................................... 20
4.1.7
Emend ...................................................................................................................... 21
4.1.8
Creon ....................................................................................................................... 21
4.2
Pipeline Analysis .............................................................................................................. 22
4.2.1 Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis (2014 – 2022) .......................................................................................................................... 22 4.2.2
BEKINDA (RHB-104) .................................................................................................. 23
4.2.3
RHB-105 (H. pylori) ................................................................................................... 23
2
4.2.4
RHB 104 (GI/Inflammation) ...................................................................................... 23
4.2.5
Relamorelin .............................................................................................................. 23
4.2.6
Viberzi ...................................................................................................................... 24
4.2.7
mAbs Stelara (ustekinumab) ..................................................................................... 24
4.2.8
AMG-714 .................................................................................................................. 24
4.3 5
Key event analysis ............................................................................................................ 25
Global Gastrointestinal Diseases Market, by Drug Category ..................................................... 26 5.1
Overview.......................................................................................................................... 26
5.1.1
Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022. 27
5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022) ................................................................................. 27 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – ................................................................................................................................. 27
5.1.4 2022
Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & ................................................................................................................................. 28
5.2.1
GIT Anti-inflammatory...................................................................................................... 29
5.3.1 5.4
Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022) ................ 30
Other GIT Therapeutics .................................................................................................... 31
5.6.1 6
Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ..................... 30
Anti-diarrhoea.................................................................................................................. 30
5.5.1 5.6
Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) .... 29
Antiemetic ....................................................................................................................... 30
5.4.1 5.5
Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) . 29
M
5.3
PL
Antacid & Anti-Ulcerant ................................................................................................... 29
SA
5.2
E
5.1.3 2022)
Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) .. 31
Global Gastrointestinal Diseases Market, by Geography .......................................................... 32 6.1
Overview.......................................................................................................................... 32
6.1.1
Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021 ...... 32
6.1.2 2022)
Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – ................................................................................................................................. 33
6.1.3 2022
Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & ................................................................................................................................. 33
6.2
North America.................................................................................................................. 34
3
6.2.1
North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021 .. ................................................................................................................................. 34
6.2.2 North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) ................................................................................................................................. 35 6.2.3 & 2021 6.2.3.1
North America Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 ................................................................................................................................. 35 U.S........................................................................................................................ 35
6.2.3.1.1 Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 35 6.2.3.2
Canada ................................................................................................................. 36
6.2.3.2.1 Gastrointestinal Diseases Market in Canada, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 36
6.3
E
6.2.4 North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .......................................................................................................................... 36 Europe ............................................................................................................................. 37 Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37
6.3.2
Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) . ................................................................................................................................. 37
6.3.3
Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 . ................................................................................................................................. 38
M
Germany............................................................................................................... 38
SA
6.3.3.1
PL
6.3.1
6.3.3.1.1 Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Yo-Y Growth (%) ................................................................................................................. 38 6.3.3.2
France .................................................................................................................. 39
6.3.3.2.1 Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 39 6.3.3.3
Rest of the Europe ................................................................................................ 39
6.3.3.3.1 Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Y-o-Y Growth (%) .......................................................................................... 39 6.3.4 2022) 6.4
Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – ................................................................................................................................. 39
Asia-Pacific ....................................................................................................................... 40
6.4.1
Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ... 40
6.4.2 2022)
Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – ................................................................................................................................. 41
4
6.4.3 2022 6.4.3.1
Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & ................................................................................................................................. 41 India ..................................................................................................................... 41
6.4.3.1.1 Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 41 6.4.3.2
China .................................................................................................................... 42
6.4.3.2.1 Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 42 6.4.3.3
Rest of the Asia-Pacific.......................................................................................... 42
6.4.3.3.1 Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$ million) and Y-o-Y Growth (%) .......................................................................................... 42 6.4.4 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .......................................................................................................................... 42
6.5.1 2021
E
Rest of the World ............................................................................................................. 43 Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 & ................................................................................................................................. 43
PL
6.5
6.5.2 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) .......................................................................................................................... 44
Latin America........................................................................................................ 44
SA
6.5.3.1
M
6.5.3 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 ............................................................................................................................ 44
6.5.3.1.1 Gastrointestinal Diseases Market in Latin America, Market Size (US$ million) and Y-o-Y Growth (%) ....................................................................................................... 44 6.5.3.2
Middle East and Africa .......................................................................................... 45
6.5.3.2.1 Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$ million) and Y-o-Y Growth (%) .......................................................................................... 45 6.5.4 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) ............................................................................................................ 45 7
8
Competitive Landscape ............................................................................................................ 46 7.1
Market Share Analysis ...................................................................................................... 46
7.2
Key Innovators ................................................................................................................. 46
7.2.1
RedHill...................................................................................................................... 46
7.2.2
Allergan .................................................................................................................... 47
7.2.3
Shire ......................................................................................................................... 47
Company Profiles..................................................................................................................... 48
5
8.1
AstraZeneca ..................................................................................................................... 48
8.1.1
Overview .................................................................................................................. 48
8.1.2
Key Strategies........................................................................................................... 48
8.1.2.1
Strong research and development activities ......................................................... 48
8.1.2.2
Novel therapeutics in company’s product offering ................................................ 48
8.1.3 8.2
Recent Developments .............................................................................................. 49
Valeant (Salix Pharmaceuticals) ........................................................................................ 50
8.2.1
Overview .................................................................................................................. 50
8.2.2
Key Strategies........................................................................................................... 50 Strategic merger and acquisitions ......................................................................... 50
8.2.2.2
US FDA approvals ................................................................................................. 50
8.2.2.3
Strong positioning in gastrointestinal anti-inflammatory therapeutic segment ..... 51
8.2.3
Recent Developments .............................................................................................. 51
Takeda Pharmaceutical Company Limited ........................................................................ 52
PL
8.3
E
8.2.2.1
8.3.1
Overview .................................................................................................................. 52
8.3.2
Key Strategies........................................................................................................... 52 Conducting awareness programs .......................................................................... 52
8.3.2.2
US FDA approval ................................................................................................... 52
8.3.2.3
Expansion of product portfolio through acquisitions ............................................. 53
8.3.2.4
Focus on core geography markets......................................................................... 53
8.4
SA
8.3.3
M
8.3.2.1
Recent Developments .............................................................................................. 53
Shire ................................................................................................................................ 54
8.4.1
Overview .................................................................................................................. 54
8.4.2
Key Strategy ............................................................................................................. 54
8.4.2.1
Expansion through strategic acquisition ................................................................ 54
8.4.2.2
Focus on the development of therapeutics for rare diseases................................. 54
8.4.2.3
Expansion of product portfolio through innovation ............................................... 54
8.4.3 8.5
Recent Developments .............................................................................................. 55
Johnson & Johnson Private Limited .................................................................................. 56
8.5.1
Overview .................................................................................................................. 56
8.5.2
Key Strategy ............................................................................................................. 56
6
8.5.2.1 8.5.3 8.6
Recent Developments .............................................................................................. 56
Eisai Co., Ltd. .................................................................................................................... 58
8.6.1
Overview .................................................................................................................. 58
8.6.2
Key Strategy ............................................................................................................. 58
8.6.2.1
Pricing strategy to emphasize affordability ........................................................... 58
8.6.2.2
Focus on emerging market.................................................................................... 58
8.6.2.3
Transformation of product portfolio ..................................................................... 58
8.6.3 8.7
Recent Developments .............................................................................................. 59
Allergan ........................................................................................................................... 60 Overview .................................................................................................................. 60
8.7.2
Key Strategies........................................................................................................... 60 Strategic merger and acquisitions ......................................................................... 60 Recent Developments .............................................................................................. 60
PL
8.7.3
E
8.7.1
8.7.2.1
9
Focus on product development and regulatory approvals ..................................... 56
Scalar 360 Degree Market Perspective ..................................................................................... 61 9.1
Global Gastrointestinal Diseases Market Trend ................................................................ 61
Acronyms ......................................................................................................................... 62
SA
10.1
M
10 Appendix ................................................................................................................................. 62
7
List of Tables Table 1.
Definitions.................................................................................................................... 11
Table 2.
Market Summary: Global Gastrointestinal Diseases Market.......................................... 14
Table 3.
Global Gastrointestinal Diseases Market Drivers........................................................... 17
Table 4.
Global Gastrointestinal Diseases Market Restraints ...................................................... 17
Table 5. (2015)
Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis .................................................................................................................................... 19
Table 6. – 2022)
Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis (2014 .................................................................................................................................... 22
Table 7.
Key event analysis- Global Gastrointestinal Diseases Market ........................................ 25
Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022) ...................................................................................................... 27 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – .................................................................................................................................... 27
Table 10.
Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) ..... 29
Table 11.
Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) ........ 29
Table 12.
Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ......................... 30
Table 13.
Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022) .................... 30
Table 14.
Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) ...... 31
Table 15.
Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022) . .................................................................................................................................... 33
Table 16. 2022)
North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – .................................................................................................................................... 35
Table 17.
Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 36
SA
M
PL
E
Table 9. 2022)
Table 18. Gastrointestinal Diseases Market in Rest of Canada, Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 36 Table 19. North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .................................................................................................................................. 36 Table 20.
Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) 38
Table 21. Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 38 Table 22. (%)
Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y Growth .................................................................................................................................... 39
8
Table 23. Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Yo-Y Growth (%) ................................................................................................................................ 39 Table 24. 2022)
Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – .................................................................................................................................... 39
Table 25. 2022)
Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – .................................................................................................................................... 41
Table 26. (%)
Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y Growth .................................................................................................................................... 42
Table 27. (%)
Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y Growth 42
Table 28. Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$ million) and Y-o-Y Growth (%) ...................................................................................................................... 42 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 42
Table 30. – 2022)
Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country (2014 44
E
Table 29. – 2022)
PL
Table 31. Gastrointestinal Diseases Market in Latin America, Market Size (US$ million) and Y-o-Y Growth (%) 45
M
Table 32. Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$ million) and Y-o-Y Growth (%) ...................................................................................................................... 45
SA
Table 33. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .................................................................................................................................. 45 Table 34.
AstraZeneca – Company Overview ............................................................................... 48
Table 35.
Valeant – Company Overview ....................................................................................... 50
Table 36.
Takeda Pharmaceutical Company Limited – Company Overview................................... 52
Table 37.
Shire – Company Overview ........................................................................................... 54
Table 38.
Johnson & Johnson Private Limited – Company Overview ............................................ 56
Table 39.
Eisai Co., Ltd. – Company Overview .............................................................................. 58
Table 40.
Allergan– Company Overview....................................................................................... 60
Table 41.
Global Gastrointestinal Diseases Market Trend ............................................................ 61
Table 42.
List of Acronyms ........................................................................................................... 62
9
List of Figures Research Methodology................................................................................................. 12
Figure 2.
Gastrointestinal Diseases Market, By Drug Category..................................................... 12
Figure 3.
Gastrointestinal Diseases Market, By Geography .......................................................... 13
Figure 4. 2022)
Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 15
Figure 5. 2021)
Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 15
Figure 6.
Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 .... 27
Figure 7. 2022
Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 28
Figure 8.
Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021 .......... 32
Figure 9.
Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022 33
E
Figure 1.
North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021 34
Figure 11. 2021
North America Gastrointestinal Diseases Market Size (US$ illion), By Country, 2016 & 35
Figure 12.
Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37
Figure 13.
Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2022 38
Figure 14.
Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ... 40
Figure 15. 2022
Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 41
Figure 16. 2021
Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 & 43
SA
M
PL
Figure 10.
Figure 17. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 44 Figure 18.
Market Share Analysis of Key Players ........................................................................ 46
10
1 Market Overview 1.1 Definitions Table 1.
Definitions
Segment
Drugs Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid, Takepron, Pentozol, Pariet/Aciphex, Carafate/Sulcrate, Cytotec, and Selbex
GIT Anti-inflammatory
Lialda, Delzicol, Asacol, Pentasa, Uceris, Apriso, Entyvio, Simponi /Simponi Aria, and Remicade
Antiemetic Agent
Emend, Aloxi, Kytril and others
Anti-diarrhoea Agent
Enterogermina, Smecta, Imodium, Bioflor, Seirogan A and others
Other GIT Therapeutics
Creon, Donnatal, Daikenchuto, Bifico, Linzess (US)/Constella, and others
Pipeline Drugs
BEKINDA (RHB-102), RHB-105 (H. pylori), RHB 104, Relamorelin, Viberzi, mAbs Stelara (ustekinumab) and AMG-714
PL
E
Antacid & Anti-Ulcerant
M
Source: Scalar Market Research Analysis
1.2 Research Methodology
SA
The research methodology for market research reports at Scalar Market Research includes a combination of top-down and bottom-up research formats. Continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensure high quality data that can be leveraged for actionable insights. The global market for gastrointestinal diseases involves the study of different branded and generic gastrointestinal therapeutics. The 'Global Gastrointestinal Diseases Market – Industry Analysis, Market Size and Forecast (2014–2022)' report includes market size and forecast, estimated from the period 2016 to 2022. This report encompasses a detailed study for various gastrointestinal therapeutic used for the treatment of conditions such as ulcerative colitis, irritable bowel diseases, celiac diseases, and many others. Drug category segment is primarily categorized into Antacid & Anti-Ulcerant, GIT Anti-inflammatory,
Antiemetic
Agent,
Anti-diarrhoea
Agent
and
Other
GIT
Therapeutics. The market size and forecast for each drug category type has been
11
provided for the period 2014 to 2022, considering 2014 and 2015 as the base year. The report also provides the compounded annual growth rate and due to (% CAGR) for the forecast period 2016 to 2022 for each drug category. Based on Geography, the market is segmented as North America, Europe, AsiaPacific and Rest of the World (RoW). The market size and forecast for geography has been estimated for the period 2014 to 2022 in terms of revenue (US$ million). The report also estimates the compounded annual growth rate (CAGR %) during the forecast period from 2016 to 2022 for all the geographies mentioned above.
Figure 1. Research Methodology
E
Top-down
Global
Segment-specific Market Size
M
Market-specific Revenues of Key Market Players
Global Market Size
PL
Market Size
SA
Revenues of Key Market Players
Regional Market Size
Bottom-up
Source: Scalar Market Research Analysis
1.3 Market Segmentation Figure 2. Gastrointestinal Diseases Market, By Drug Category
Source: Scalar Market Research Analysis
12
Figure 3. Gastrointestinal Diseases Market, By Geography
SA
M
PL
E
Source: Scalar Market Research Analysis
13
2 Executive Summary The global gastrointestinal diseases market was estimated to be US$XX million in 2016. This market is expected to grow at a CAGR of XX% in the forecast period and is expected to be US$XX billion in 2022. This report segments the global gastrointestinal diseases market by drug category and geography.
2.1 Market Summary: Global Gastrointestinal Diseases Market Table 2.
Market Summary: Global Gastrointestinal Diseases Market Factors
Global Gastrointestinal Diseases Market (US$ million)
2016
2022
17,271.2
14,859.7
E
Largest Revenue Generating Market, by Drug Category (US$ million)
SA
Largest Revenue Generating Market, by Geography (US$ million)
M
Segment with Highest Growth Rate, by Drug Category
PL
Lowest Revenue Generating Market, by Drug Category (US$ million)
Lowest Revenue Generating Market, by Geography (US$ million)
Segment with Highest Growth Rate, by Geography Key Market Players (2015) Pipeline Drugs
Source: Scalar Market Research analysis
14
2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022) Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022)
2016
2022 10.1% 2.4%
12.0%
3.6%
Antacid & AntiUlcerant GIT Anti40.7% inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT Therapeutics
8.2% 12.5%
45.2%
38.6%
E
26.7%
PL
Source: Scalar Market Research analysis
Of the different drug category, antacid & anti-ulcerant accounted for the largest share of the global market revenue. Growth of this segment is majorly attributed to the
M
approval of novel proton pump inhibitors by government regulatory. In addition, growing demand for gastrointestinal therapeutics such as Nexium, Dexilant, and
SA
Sulcrate in developing as developed countries drives the market growth of this segment. However, anti-diarrohea segment recorded around 3.5% share of the global market and is expected lose its market share during the forecast period owing to the generic drug entry.
2.1.2 Global Gastrointestinal Diseases Geography (2016 vs. 2022)
Market
Size (US$
million),
By
Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2022)
15
3 Market Dynamics 3.1 Drivers Table 3.
Global Gastrointestinal Diseases Market Drivers Drivers
2014-16
2017- 19
2020-22
● ◕ ◑
● ◕ ●
● ● ●
Source: Scalar Market Research Analysis
E
Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact
Global Gastrointestinal Diseases Market Restraints
M
Table 4.
PL
3.2 Restraints
SA
Restraints
2014-16
2017- 19
2020-22
◑ ◕
● ◑
◕ ◑
Source: Scalar Market Research Analysis
Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact
3.3 Opportunities Development of biologic therapeutics for the treatment of gastrointestinal diseases due to its favorable safety profile Development of monoclonal antibody related gastrointestinal therapeutics Increasing investment in emerging market of Asia-Pacific
17
3.4 Premium Industry Trends ďƒ˜ Companies focusing on Irritable Bowel Diseases with Diarrhoea therapeutics
SA
M
PL
E
will serve as potential market to record high growth profit
18
5 Global Gastrointestinal Diseases Market, by Drug Category 5.1 Overview The global gastrointestinal diseases market is categorized into different types of drug category such as Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic, Antidiarrhoea, and other GIT Therapeutics. This chapter analyzes the market revenue generated by the different branded and generic therapeutics falls under different drug categories. Antacid and Anti-Ulcerant section covers the study of variety of Omeprazole drugs such as Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid, Takepron,
Pentozol,
Pariet/Aciphex,
and
drugs
such
as
Sucralfate
(Carafate/Sulcrate) , Cytotec and others. Companies such as AstraZeneca, Takeda Pharmaceuticals and Daichi Sankyo are aggressively investing in research and development activities to develop new anti-ulcerant moieties which help this segment
E
to grow during the forecast period. However, negative growth of the segment is
PL
majorly attributed to the patent expiry of AstraZeneca’s two brand drug, Losec/Prilosec and Nexium. On other side, the demand for Takeda Pharmaceutical’s proton pump inhibitor (Dexilant) is increasing due to its unique mechanism of action
M
which is considered as positive impact for the growth of this segment. GIT Anti-inflammatory comprises drugs such as Lialda, Delzicol, Asacol, Pentasa,
SA
Uceris, Apriso, Entyvio, Remicade, and others. This segment is anticipated to growth with the positive growth rate of XX% during the forecast year 2016 to 2022. The growth of the segment is majorly supported by the launch of Takeda’s vedolizumab category of drug (Entyvio). This monoclonal antibody based Anti-inflammatory drug is expected to hit the market with highest growth rate due to its high efficacy for the treatment of gastrointestinal diseases. Additionally, drug molecules such as Lialda (Shire, Inc.) and Apriso (Salix Pharmaceutical) is also projected to support the growth of this market segment owing to the patent exclusivity. Antiemetic drug agents include the market estimation covering brand or generic drugs such as Emend, Aloxi, Kytril and many others. Study for the gastrointestinal drugs such as Enterogermina, Smecta, Imodium, and others are covered under the anti-diarrhoea drug segment. While, Other GIT Therapeutics includes the revenue generation
of
therapeutics
such
as
Linzess/Constella, and many others.
26
Donnatal,
Creon,
Daikenchuto,
5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 2016
2022 10.1% 2.4%
12.0%
3.6%
Antacid & AntiUlcerant GIT Anti40.7% inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT Therapeutics
8.2% 12.5%
45.2%
38.6%
E
26.7%
PL
Source: Scalar Market Research Analysis
Drug
Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022)
SA
Table 8.
M
5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022)
2014
Global Commercialize Drug Revenue Global Pipeline Drug Revenue
2015
2016
2017
2018
2019
2020
2021
2022
CAGR% (2016 – 2022)
74.5%
Total Source: Scalar Market Research Analysis
5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) Table 9.
Drug Category
Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category(2014 – 2022) 2014
2015
2016
2017
2018
27
2019
2020
2021
2022
CAGR% (2016 – 2022)
Antacid & Anti-Ulcerant GIT Antiinflammatory Antiemetic Antidiarrhoea Other GIT Therapeutics
642.2
Total Source: Scalar Market Research Analysis
5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022
PL
E
Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022
5,729.9 4,619.0
SA
US$ million
6,045.6
M
7,798.4
2,152.0
2,080.6 1,505.5
1,215.8
621.2
Antacid & AntiUlcerant
GIT Anti-inflamatory
Antiemetic Agent
2016
2022
Source: Scalar Market Research Analysis
28
363.0
Anti-diarrhoea Agent
Other GIT Therapeutics
5.2 Antacid & Anti-Ulcerant 5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) Regions
2014
2015
2016
2017
2018
2019
2020
2021
2022
CAGR% (2016 – 2022)
North America Europe
442.8
PL
Rest of the World
E
Asia-Pacific
Total
M
Source: Scalar Market Research Analysis
5.3 GIT Anti-inflammatory
SA
5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) Regions
2014
2015
2016
2017
2018
2019
2020
2021
2022
CAGR% (2016 – 2022)
North America Europe Asia-Pacific Rest of the World 3.7%
Total Source: Scalar Market Research Analysis
29
6 Global Gastrointestinal Diseases Market, by Geography 6.1 Overview The global gastrointestinal diseases market, by geography is categorized into North America, Europe, Asia-Pacific, and Rest of the World. This chapter analyzed the revenue generation by each region in terms of US$ million. The global market for gastrointestinal diseases is majorly dominated by the developed regions of North America and Europe which captured almost XX% share of the global market revenue in 2016. Growth of this region is majorly attributed to the rising approval of novel gastrointestinal
therapeutics
coupled
with
growing
incidence
of
various
gastrointestinal diseases. Among which, North America is accounted for XX% share of the total revenue in 2016. Approval of GIT Anti-inflammatory such as Lialda and Entyvio helped the region to grow with steady growth rate during the forecast period.
E
However, increasing incidence of gastrointestinal diseases such as irritable bowel
PL
syndrome and ulcerative colitis in Asia-Pacific and Rest of the World region drives
M
the growth of the market during the future period.
SA
6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2022 Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2022
2022
2016 9.5%
4.0%
9.4%
North America
3.6%
Europe
50.5%
50.6% 35.9%
Asia
36.4% Rest of the World
Source: Scalar Market Research Analysis
32
6.1.2 Global Gastrointestinal Diseases Geography (2014 – 2022) Table 15. Global Gastrointestinal Geography(2014 – 2022) Geography
2014
2015
2016
Market
Diseases
2017
Market
2018
2019
Size (US$
Size
2020
(US$
2021
million),
By
million),
By
2022
CAGR% (2016 – 2022)
North America Europe Asia-Pacific Rest of the World
761.1
E
Total
Diseases Market
Size (US$
million),
M
6.1.3 Global Gastrointestinal Geography, 2016 & 2022
PL
Source: Scalar Market Research Analysis
By
SA
Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022 8,745.8
7,511.1
US$ million
6,205.5 5,411.3
1,635.21,401.6 684.8 535.7
North America
Europe
Asia 2016
Source: Scalar Market Research Analysis
33
2022
Rest of the World
6.2 North America North America recorded US$ XX million revenue, around 50.64% share of the global gastrointestinal diseases market. Gastrointestinal diseases market in North America is majorly supported by the favorable government initiatives to introduce novel GIT therapeutics.
For
example,
in
May
2014,
U.S.
FDA
approved
Takeda
Pharmaceuticals’ GIT Anti-inflammatory therapeutic, Entyvio. The drug is indicated for the treatment of severe ulcerative colitis and moderate to severe Crohn‘s disease. Takeda Pharmaceutical is projecting high sales growth of this integrin receptor antagonist in the U.S. market owing to its proven safety and efficacy in clinical trials for the treatment of ulcerative colitis and Crohn‘s disease. Additionally, in November 2013, the U.S. Centers for Disease Control and Prevention estimated
E
that more than 21 million people in the U.S. get infected with noro-virus and develop
PL
acute gastroenteritis each year which further stimulated the demand for GIT therapeutics. However, patent expiry of blockbuster gastrointestinal therapeutics such as Nexium, Pariet/Aciphex and many others adversely affected the growth of
SA
M
the market.
6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 2016
2022
12.9%
15.9%
U.S.
Canada
84.1%
87.1%
Source: Scalar Market Research Analysis
34
7 Competitive Landscape 7.1 Market Share Analysis Figure 18. Market Share Analysis of Key Players Allergan
Market Share (Value %), 2015 8.3%
AstraZeneca 15.0% Takeda Pharmaceutical Company Limited Daichi Sankyo
55.4% 12.6% Eisai Co., Ltd.
Other
PL
E
3.6% 5.0%
Source: Annual Reports, Press Releases & Scalar Market Research analysis
SA
7.2.1 RedHill
M
7.2 Key Innovators
RedHill is an emerging biopharmaceutical company, primarily focused on commercialize and development of molecules for the treatment of gastrointestinal and inflammatory diseases. This company is considered as one of the growing company
owing
to
the
impressive
late-stage
clinical
pipeline
drugs
for
gastrointestinal diseases. The company investigates gastrointestinal therapeutics namely Bekinda, RHB-105 and RHB-104 under the phase - 3 clinical study which is expected to hit the market in between 2018 - 2019. Among which, Bekinda contains Ondansetron drug, filed for the antiemetic indication. The drug is primarily used to prevent radiation-induced nausea and vomiting. Additionally, the company has initiated a Phase - 2 clinical study with Bekinda for the treatment of Irritable bowel syndrome with diarrhoea. Furthermore, the company is also investigating therapeutics for the treatment of H. pylori infection (RHB-105) and Crohn’s disease (RHB-104). Thus, it looks that the company have very interesting market potential to
46
8 Company Profiles 8.1 AstraZeneca 8.1.1 Overview
Table 34. AstraZeneca – Company Overview AstraZeneca - Company Detail London, UK
Year of Establishment
1999
No. of Employees (2015)
More than 50,000
Gastrointestinal Therapeutics
Losec/Prilosec and Nexium
Revenue (2015)
US$ 23,641 million
E
Headquarters
Source: Annual Reports, Investor Presentations,Primary Interviews andScalar Market Research Analysis
PL
8.1.2 Key Strategies
8.1.2.1 Strong research and development activities
M
AstraZeneca is one of the key leaders for the global gastrointestinal drugs market. The company is aggressively focusing on developing novel gastrointestinal
SA
therapeutics for the treatment of conditions such as ulcerative colitis, irritable bowel syndrome and Crohn’s diseases. In 2015, the company spent US$ 5,997 million for research and development activities, up 7% as compared to the previous year. The company aimed to develop new medicines notably in the segment of diabetes and gastrointestinal diseases. 8.1.2.2 Novel therapeutics in company’s product offering
Owing to the strong research and development focus on gastrointestinal disease segment, the company has developed novel therapeutics which has shown high efficacy and safety for the treatment of GIT disorders. For example, the company offers three gastrointestinal drugs such as Entocort (budesonide), Losec/Prilosec (omeprazole) and Nexium (esomeprazole magnesium). These drugs are used for the treatment and cure of GIT problems such as inflammatory bowel disease and acid related disorders.
48
8.1.3 Recent Developments
Pfizer acquired the exclusive global rights to market AstraZeneca’s Nexium for OTC indications worldwide in 2012, and launched OTC Nexium 20mg in the US and Europe in 2014. In November 2015, the company entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort, a gastroenterology medicine for patients with mild to moderate Crohn’s disease. Under this
M
PL
E
agreement, Perrigo acquired the right to sell Entocort capsules
SA
49
10 Appendix 10.1 Acronyms Table 42. List of Acronyms Acronym
Expansion
IBS-D
Irritable Bowel Syndrome with Diarrhea
H. pylori
Helicobacter Pylori
GIT Disease
Gastrointestinal Disease
U.S. FDA
U.S. Food and Drug Administration
DDW
Digestive Disease Week
SA
M
PL
E
Source: Scalar Market Research Analysis
62